Global Oncology Based In Vivo Cro Market Size 2024, Forecast To 2033
6 Mar, 2024
The oncology based in-vivo CRO market size has grown strongly in recent years. It will grow from $1.27 billion in 2023 to $1.38 billion in 2024 at a compound annual growth rate (CAGR) of 8.4%. The growth in the historic period can be attributed to increasing focus on oncology therapeutics, increasing incidence of cancer, shift towards personalized medicine, pharmaceutical industry growth, demand for target-specific therapies. The oncology based in-vivo CRO market size is expected to see strong growth in the next few years. It will grow to $2 billion in 2028 at a compound annual growth rate (CAGR) of 9.7%. The growth in the forecast period can be attributed to emerging market opportunities, shift towards immuno-oncology therapies, rise in oncology clinical trials, precision medicine and targeted therapies. Major trends in the forecast period include regenerative medicine and cell therapies, demand for faster drug development, digitalization and data analytics, focus on tumor microenvironment, rise in biologics and immunotherapies.
Global Oncology Based In Vivo CRO Market Key Driver
The growing prevalence of cancer is expected to propel the growth of the oncology-based in-vivo CRO market going forward. Cancer refers to a group of diseases in which abnormal cells divide uncontrollably, go beyond their usual boundaries, originate in almost any organ or tissue of the body, and spread through the blood and lymph systems to other parts of the body. Treatment and diagnosis of cancer require innovative drugs and devices, which undergo different preclinical trials, clinical trials, and regulatory processes before they enter the market. An oncology in-vivo-based CRO is a company hired by a sponsor company that provides research services such as performing complete or partial steps of running a preclinical in-vivo study (testing or with living organisms such as animals, plants, or whole cells) before the drug or device is trialed in humans. With the increasing prevalence of cancer, the demand for innovative treatments and therapies has also increased, driving the growth of the oncology-based in-vivo CRO market. For instance, in 2021, according to the journal published by the American Chemical Society (ACS), a US-based non-profit organization that supports scientific inquiry in the field of chemistry, the global burden of cancer is expected to be 28.4 million cases in 2040, a 47% rise from 2020. The growing prevalence of cancer is driving the oncology-based in-vivo CRO market. The market size of the oncology-based in-vivo CRO market in 2023 was [insert 2023 market size], and it is projected to reach [insert 2024 market size] by 2024 and [insert 2028 market size] by 2028.
Get A Free Sample Of The Global Oncology Based In Vivo CRO Market ReportGlobal Oncology Based In Vivo CRO Market Segments
The oncology based in-vivo cro market covered in this report is segmented –
1) By Indication: Blood Cancer, Solid Tumors, Other Indications
2) By Model: Syngeneic Model, Xenograft, Patient Derived Xenograft (PDX), Other Models
3) By Application: Hospitals, Rehabilitation Centers
By Geography:The regions covered in the oncology based in-vivo cro market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain
North America was the largest region in the oncology based in-vivo CRO market in 2023. North America is expected to be the fastest-growing region in the global oncology-based in-vivo CRO market report during the forecast period. The regions covered in the oncology based in-vivo cro market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Major Oncology Based In Vivo CRO Industry Players
Crown Bioscience, Charles River Laboratories International Inc., Taconic Biosciences Inc., The Jackson Laboratory, ICON plc., WuXi AppTec Inc., Eurofins Scientific SE, Labcorp Drug Development, Champion Oncology Inc., Xentech SAS, Thermo Fisher Scientific Inc., MI Bioresearch Inc., Clintec International Private Limited, Worldwide Clinical Trials Inc., Pharm-Olam LLC, Clinipace Clinical Research Private Limited, Covance Inc., Evotec SE, Living Tumor Laboratory, Oncodesign SA, Pharmaron Beijing Co. Ltd., Syngene International Limited, GenScript Biotech Corporation, Shanghai Medicilon Inc., Oncolys BioPharma Inc., Pharmalegacy Laboratories, Oncotest GmbH, Oncovision, Biocytogen LLC, Innovent Biologics Inc.
Get The Full Global Oncology Based In Vivo CRO Market Report
Oncology Based In Vivo CRO Market Overview
An oncology-based in-vivo contract research organization (CRO) refers to a company hired by another company to perform complete or partial steps of running a preclinical in-vivo study (testing or with living organisms such as animals, plants, or whole cells), such as designing, managing, monitoring, and analyzing in-vivo preclinical results for oncology drugs or devices.
Oncology Based In Vivo CRO Global Market Report 2023 provides data on the global oncology based in vivo cro market such as market size, growth forecasts, segments and geographies, competitive landscape including leading competitors’ revenues, profiles and market shares. The oncology based in vivo cro market report identifies opportunities and strategies based on market trends and leading competitors’ approaches.